(0) View Checkout


Antioxidant & Essential Nutrient


100 Softgels 

  • Antioxidant support for good health
  • Cell protection


• Antioxidant support for good health
• Cell protection

Why Jensens Vitamins?

The application of Structurally Active-Orthogenic (SAO) technology by Jensens Vitamins’ research and production team ensures that all available products are of a heightened quality. 

SAO technology produces active ingredients with strong molecular composition and the highest bioavailability (ratio of inactive/active ingredients) in order to ensure synergistic applications occur within the body. In other words, the Jensens Vitamins label ensures that all our products are able to be optimally absorbed by the bloodstream at the molecular level, and don’t just pass through the body undigested. 

Jensens Vitamins is pharmaceutically tested and clinically verified by careful examination at every stage of production. The protocols are measured and confirmed for international standard compliance before the product is introduced to market. 

Jensens Vitamins only uses 100% natural ingredients. 

Active Ingredients

Vitamin E (400 IU)

Soybean oil, gelatin (bovine), glycerine.

*4X stronger than HerbalGenn Vitamin E 100 IU







100 Softgels 

Product Type:

Vitamin E

Cautions & Warnings:

Consult a physician prior to use if you have cancer, diabetes, or cardiovascular disease. In case of accidental overdose, contact a physician or a poison control centre. Keep out of reach of children.


St John's wort (Hypericum perforatum) is an herbal shrubby plant with clusters of yellow flowers that have oval, elongated petals, the flowers and leaves are used to make medicine. It has a history of being used as a medicine dating back to ancient Greece, where it was used for a range of illnesses, including various "nervous diorders.” Scientists believe it is native to Europe, parts of Asia and Africa, and the western United States. The plant gets its name because it is often in full bloom around June 24, the day traditionally celebrated as the birthday of John the Baptist. 

Biogenique Structurally Active-Orthogenic (SAO) technology

Biogenique SAO technology helps to extract the active components hypericin and hyperforin from St John’s wort. Hypericin and hyperforin are found to be responsible for their effects against depression. They act on chemical messengers in the nervous system that regulate mood. SAO technology establishes a higher caliber of science for better quality research and formulation. It makes sure that the compounds are delivered on their potential to create effectiveness.

SAO Analysis

Hypericum perforatum:
Extracts of Hypericum perforatum (St. John's wort) have been recommended traditionally for a wide range of medical conditions. Our studies report St. John's wort to be more effective than placebo and equally effective as tricyclic antidepressant drugs in the short-term treatment of mild-to-moderate major depression (1-3 months). Overall, the scientific evidence supports the effectiveness of St. John's wort in mild-to-moderate major depression. The evidence in severe major depression remains unclear. An oil can be made from St. John’s wort. Some people apply this oil to their skin to treat bruises and scrapes, inflammation and muscle pain, first degree burns, wounds, bug bites, hemorrhoids, and nerve pain. But applying St. John’s wort directly to the skin is risky. It can cause serious sensitivity to sunlight. 

Scientific Evidence


There is good evidence that St. John's wort may reduce symptoms in people with mild-to-moderate but not severe (or major) depression. In many studies it seems to work as well as selective serotonin reuptake inhibitors (SSRIs), a popular type of antidepressant that doctors often prescribe first to treat depression. They include fluoxetine (Prozac), citalopram (Celexa), and sertraline (Zoloft). In addition, St. John’s wort doesn’t seem to have one of the most common side effects of antidepressants, which is loss of sex drive. Not all studies agree, however. In one study, St. John's wort was found to be no more effective than placebo for treating depression. But these studies should be weighed against the majority that have found St. John’s wort helps depression. For example, in the same study, Zoloft also failed to show any benefit in treating depression. Many other studies have compared St. John's wort to Prozac, Celexa, paroxetine (Paxil), and Zoloft, and found that the herb works as well as the drug. Other studies are ongoing. 

Obsessive-compulsive disorder (OCD)

There are a few reported cases of possible benefits of St. John's wort in patients with obsessive-compulsive disorder (OCD). Currently there is not enough scientific evidence to recommend St. John's wort for this condition 

Depressive disorder (mild-to-moderate)

St. John's wort has been extensively studied in Europe over the last two decades, with more recent research in the United States. Short-term studies (1-3 months) suggest that St. John's wort is more effective than placebo (sugar pill), and equally effective as tricyclic antidepressants (TCAs) in the treatment of mild-to-moderate major depression. Comparisons to the more commonly prescribed selective serotonin reuptake inhibitor (SSRI) antidepressants, such as fluoxetine (Prozac®) or sertraline (Zoloft®), are more limited. However, other data suggest that St. John's wort may be just as effective as SSRIs with fewer side effects. Safety concerns exist as with most conventional and complementary therapies. 

Somatoform disorders

Somatoform disorders show physical symptoms that cannot be attributed to organic disease and appear to be of psychic origin. Early evidence shows that St. John's wort may help with somatoform disorders. Further research is needed to confirm these results. 


• The use of herbs is a time-honored approach to strengthening the body and treating disease. Herbs, however, can trigger side effects and can interact with other herbs, supplements, or medications. For these reasons, you should take herbs with care, under the supervision of a health care provider.

• St. John's wort should not be used to treat severe depression. You should see a doctor to make sure you have the right diagnosis before taking St. John's wort. Your doctor can help you determine the right dose and make sure you are not taking any other medications that might interact with St. John's wort.

• Side effects from St. John's wort are generally mild and include stomach upset, hives or other skin rashes, fatigue, restlessness, headache, dry mouth, and feelings of dizziness or mental confusion. St. John's wort can also make the skin overly sensitive to sunlight, called photodermatitis.

• Other potential concerns about St. John’s wort are that it may interfere with getting pregnant or make infertility worse; that it may make symptoms of ADD and ADHD worse, especially among people taking methylphenidate; that it may increase the risk of psychosis in people with schizophrenia; and that it may contribute to dementia in people with Alzheimer’s. More study is needed, however.

• Do not take St. John's wort if you have bipolar disorder. There is concern that people with major depression taking St. John’s wort may be at a higher risk for mania.

• Women who are pregnant, trying to become pregnant, or breastfeeding should not take St. John’s wort 

Interactions you should know

• St. John's wort interacts with a large number of medications. If you are being treated with any medications, you should not use St. John's wort without first talking to your doctor. St. John’s wort may interact with these medications:

• Antidepressants -- St. John's wort may interact with medications used to treat depression or other mood disorders, including tricyclic antidepressants, SSRIs, and monoamine oxidase inhibitors (MAOIs). Taking St. John's wort with these medications tends to increase side effects, and could lead to a dangerous condition called serotonin syndrome. Do not take St. John's wort with other antidepressants, including:o SSRIs: Citalopram (Celexa), escitalopram (Lexapro), fluvoxamine (Luvox), paroxetine (Paxil), fluoxetine (Prozac), sertraline (Zoloft)
o Tricyclics: Amitriptyline (Elavil), nortryptyline (Pamelor), imipramine (Tofranil)
o MAOIs: Phenelzine, (Nardil), tranylcypromine (Parnate)
o Nefazodone (Serzone)

• Allergy drugs (antihistamines) -- St. John's wort may reduce levels of these drugs in the body, making them less effective: Loratadine (Claritin), Cetirizine (Zyrtec), Fexofenadine (Allegra)

• Clopidogrel (Plavix) -- Theoretically, taking St. John’s wort along with clopidogrel may increase the risk of bleeding.

• Birth control pills -- There have been reports of breakthrough bleeding in women on birth control pills who were also taking St. John's wort. It is possible that the herb might make birth control pills less effective, leading to unplanned pregnancies.

• Sedatives -- St. John's wort can increase the effect of drugs that have a sedating effect, including:
o Anticonvulsants, such as phenytoin (Dilantin) and valproic acid (Depakote)
o Barbiturates
o Benzodiazepines, such as diazepam (Valium)
o Drugs to treat insomnia, such as zolpidem (Ambien), zaleplon (Sonata), eszopiclone (Lunesta), and ramelteon (Rozerem)
o Tricyclic antidepressants, such as amitriptyline (Elavil)
o Alcohol

• Triptans (used to treat migraines) -- St. John's wort can increase the risk of side effects, including serotonin syndrome, when taken with these medications: Naratriptan (Amerge), Rizatriptan (Maxalt), Sumatriptan (Imitrex), Zolmitriptan (Zomig)

• Warfarin (Coumadin) -- St. John's wort reduces the effectiveness of warfarin, an anticoagulant (blood-thinner). 

Selected references

1. Briese V, Stammwitz U, Friede M, et al. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment--results of a large-scale, controlled, observational study. Maturitas 2007 Aug 20;57(4):405-14.

2. Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J 2007 Apr 30;48(2):289-94.

3. Franklin M, Hafizi S, Reed A, et al. Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and cortisol concentrations in healthy male volunteers. Pharmacopsychiatry 2006 Jan;39(1):13-5.

4. Kasper S, Volz HP, Moller HJ, et al. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol 2008;18(11):803-813. 5. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;(4):CD000448.

6. Muller T, Mannel M, Murck H, et al. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004;66(4):538-547.

7. Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005 Jun;71(6):402-8.

8. Randlov C, Mehlsen J, Thomsen CF, et al. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine 2006 Mar;13(4):215-21.

9. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005454.

10. Sardella A, Lodi G, Demarosi F, et al. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. J Oral Pathol Med 2008;37(7):395-401.

11. Schempp CM, Windeck T, Hezel S, et al. Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled, double blind half-side comparison. Phytomedicine 2003;10 Suppl 4:31-37.

12. Schulz V. Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine 2006 Feb;13(3):199-204.


I)Modulation Of Oxidative Stress And Cab+ Mobilization Through Trpm2 Channels In Rat Dorsal Root Ganglion Neuron By Hypericum Perforatum.


Naz?ro?lu M1, Ci? B2, Ozgül C2. 


A main component of St. John's Wort (Hypericum Perforatum, HP) is hyperforin which has antioxidant properties in dorsal root ganglion (DRG) neurons, due to its ability to modulate NADPH oxidase and protein kinase C. Recent reports indicate that oxidative stress through NADPH oxidase activates TRPM2 channels. HP may be a useful treatment for Ca2+ entry and oxidative stress through modulation of TRPM2 channels in the DRG. We aimed to investigate the protective role of HP on Ca2+ entry and oxidative stress through TRPM2 channels in DRG neurons of rats. The native rat DRG neurons were used in whole-cell patch clamp, Fura-2 and antioxidant experiments. Appropriate, nontoxic concentrations and incubation times for HP were determined in the DRG neurons by assessing cell viability. The H2O2-induced TRPM2 currents were inhibited by 2-aminoethyldiphenyl borate (2-APB) and N-(p-amylcinnamoyl)anthranilic acid (ACA). TRPM2 current densities and cytosolic free Ca2+ concentration in the neurons were also reduced by HP (2 and 24 hours). In Fura-2 experiments, cytosolic Ca2+ mobilization was reduced by voltage-gated calcium channel blockers (verapamil+diltiazem, V+D) and HP. Glutathione peroxidase activity and GSH values in the DRG were high in HP, 2-APB and V+D groups although lipid peroxidation level was low in the groups. In conclusion, we observed a protective role for HP on Ca2+ entry through a TRPM2 channel in the DRG neurons. Since over-production of oxidative stress and Ca2+ entry are implicated in the pathophysiology of neuropathic pain and neuronal inflammation, our findings may be relevant to the etiology and treatment of neuropathology in DRG neurons. 

II)Comparative evaluation of the activity of plant infusions against Helicobacter pylori strains by three methods.


Boyanova L.
Author information
• Department of Medical Microbiology, Medical University of Sofia, Zdrave Street 2, 1431, Sofia, Bulgaria, l.boyanova@hotmail.com. 


The aim of the study was to assess the activities of six plant infusions against Helicobacter pylori strains using a comparative screening assay (CSA), agar-well diffusion method (AWDM) and microscopy. Green tea, St John's wort (SJW), rooibos, peppermint, chamomile and lime flower aqueous infusion concentrations were chosen to mimic those in herbal teas/tisanes. CSA concentrations were 4.5 mg ml-1 for chamomile and 6.8 mg ml-1 for the other agents. AWDM amounts were 0.4 mg/well for the chamomile and 0.6 mg/well for the other agents. Using CSA, ≥8 × 104 colony forming unit reduction was found in >60 % of the strains by the green tea (81.5 %), SJW (75.9 %) and rooibos (63.0 %) within 2 h. Similarly, by AWDM, the activity against >60 % of the strains was found by the green tea, SJW and rooibos. Gram staining results were alike, showing mostly/only coccoids in >66 % of the strains by the same three agents within 2 h. Lime flowers showed the lowest activity by all methods. In conclusion, CSA allows comparing the activities of many agents against numerous strains. To our knowledge, these are the first data about rooibos and lime flower activities against H. pylori. All the three methods revealed that the most active agents were the green tea, SJW and rooibos, which also possess additional beneficial properties, e.g. antioxidant, anti-inflammatory and antitumor effects, therefore these plants may have a beneficial use as prophylactic agents against or adjuvants in the therapy of H. pylori infection. 

III)Evidence for contributions of interactions of constituents to the anti-inflammatory activity of hypericum perforatum.


Hammer KD, Birt DF.
Author information 
• a Center for Research on Botanical Dietary Supplements , Iowa State University , Ames , Iowa , USA. 


Hypericum perforatum (Hp) extracts contain many different classes of constituents including flavonoids and biflavonoids, phloroglucinols, naphthodianthrones, caffeic acid derivatives, and unknown and/or unidentified compounds. Many constituents may be responsible for the anti-inflammatory activity of Hp including quercetin and derivatives, hyperforin, pseudohypericin, and amentoflavone. In line with antidepressant data, it appears that the interactions of constituents may be important for the anti-inflammatory activity of Hp. Interactions of constituents, tested in bioavailability models, may explain why synergistic mechanisms have been found to be important for antidepressant and antiproliferative bioactivities. This review highlights the relationship among individual constituents and the anti-inflammatory activity of Hp extracts and proposes that interactions of constituents may be important for the anti-inflammatory activity of botanical extracts, although the exact mechanisms of the interactions are still unclear. 

IV)Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety.


Liu YR, Jiang YL, Huang RQ, Yang JY, Xiao BK, Dong JX.
Author information 
• * School of Pharmaceutical Engineering, Shenyang Pharmaceutical University , Shenyang. 


Objective To compare by meta-analysis the efficacy and adverse events of Hypericum perforatum L. (St. John's Wort), or its combinations, and placebo for menopausal women. Design A systematic review and meta-analysis were carried out by searching in Pubmed, Cochrane Library, Embase and the Web of Science database. Results Extracts of Hypericum perforatum L. and its combination with herbs were significantly superior to placebo (standard mean difference = -1.08; 95% confidence interval -1.38 to -0.77); extracts of Hypericum perforatum L. proved to be more effective than placebo in the treatment of menopause. Adverse events occurred in 53 (17.4%) patients on Hypericum perforatum L. preparations and 45 (15.4%) patients on placebo (relative risk = 1.16; 95% confidence interval 0.81-1.66). Conclusion Extracts of Hypericum perforatum L. have possibly fewer side-effects than placebo for the treatment of menopausal women. 

V)Treatment of premenstrual dysphoric disorder.


Rapkin AJ, Lewis EI.
Author information 
• Department of Obstetrics & Gynecology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Room 27-139 CHS, Los Angeles, CA 90095-1740, USA. 


Premenstrual dysphoric disorder (PMDD) is comprised of a cluster of affective, behavioral and somatic symptoms recurring monthly during the luteal phase of the menstrual cycle. The disorder affects 3-8% of menstruating women and represents the more severe and disabling end of the spectrum of premenstrual disorders, which includes premenstrual syndrome and premenstrual aggravation of underlying affective disorder. Rigorous and specific diagnostic criteria for PMDD were specified in the Diagnostic and Statistical Manual of Mental Disorders IV (1994) and reaffirmed in the Diagnostic and Statistical Manual of Mental Disorders V (2013) and, consequently, there has been a marked increase in well-designed, placebo-controlled studies evaluating treatment modalities. Although the exact pathogenesis of PMDD is still elusive, treatment of PMDD and severe premenstrual syndrome has centered on neuromodulation via serotonin reuptake inhibitor antidepressants, and ovulation suppression utilizing various contraceptive and hormonal preparations. Unlike the approach to the treatment of depression, serotonergic antidepressants need not be given daily, but can be effective when used cyclically, only in the luteal phase or even limited to the duration of the monthly symptoms. Less, well-substantiated alternative treatments, such as calcium supplementation, agnus castus (chasteberry), Hypericum perforatum (St John's wort) and cognitive/behavioral/relaxation therapies, may be useful adjuncts in the treatment of PMDD. This review provides an overview of current information on the treatment of PMDD. 


Customers who bought this item also bought: